Most Read Articles
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
6 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Pearl Toh, 3 days ago
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.

Serum aluminium tied to uraemic pruritus during haemodialysis

04 Dec 2018

Concentrations of aluminium in the serum may be correlated with uraemic pruritus (UP) development in patients receiving maintenance haemodialysis (HD), reports a recent study.

Researchers performed a cross-sectional analysis of 866 patients (mean age 56.18±13.59 years; 440 males) undergoing maintenance HD for a mean of 6.96±5.35 years. In this group, the median serum aluminium was 0.9 µg/dL and 21.8 percent (n=189) had UP. Serum aluminium in those with UP were significantly higher than in those without (p<0.001).

Using a threshold value of 2 µg/dL, researchers classified participants into those with high (n=119) or low (n=747) serum aluminium. The proportion of patients with UP was significantly higher in the former group (34.5 percent vs 19.8 percent; p=0.001).

Multivariate logistic regression analysis further showed that the log of serum aluminium concentration was a significant risk factor for UP development (odds ratio [OR], 5.64; 95 percent CI, 3.13–10.17; p<0.001). Moreover, having serum aluminium 2 µg/dL was also associated with a higher UP risk (OR, 2.38; 1.49–3.79; p<0.001).

Other potential risk factors included body mass index, serum levels of cholesterol, albumin and low-density lipoprotein, duration of haemodialysis, normalized protein catabolism rate, and comorbidities such as diabetes mellitus and hepatitis C virus infection. However, the significance of these were attenuated upon multivariable adjustments.

Limitations of the present study included its cross-sectional and single-centre design, as well as the lack of information regarding the aluminium content of the participants’ diets, said researchers. Further research is thus needed to determine the role of aluminium on UP development.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
6 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Pearl Toh, 3 days ago
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.